BACKGROUND: Peak oxygen consumption (VO2) predictive authority in heart failure (HF) has been established from male cohorts. We evaluated the gender impact on the prognostic meaning of low peak VO2. METHODS: We followed 529 HF patients (116 female), with peak VO2 ≤ 14 mL/kg/min, until cardiovascular death (CVD) and urgent heart transplantation. RESULTS: During follow up, 156 (29%) patients had cardiac events. Female gender, age, left ventricular ejection fraction, peak VO2, peak systolic blood pressure, and beta-blocker treatment all contributed to increase the risk ability of the hierarchical multivariate model. Two-year survival was higher in women: 85 vs 66%; χ(2)=15.7, p<0.0001. Peculiarly, outcome results were similar when only CVD was considered. Females showed a multivariate adjusted hazard ratio (HR) of 0.46. Since a 1-mL/kg/min increment in peak VO2 was equated with a 12% improvement in prognosis, the same gender adjusted HR was achieved when mean peak VO2 was reduced by 5 units in women: thus, a HF woman with peak VO2 of 9 mL/kg/min has the same 2-year outcome as a HF man with peak VO2 of 14 mL/kg/min. CONCLUSIONS: Although HF women have a comparatively lower peak VO2 than men, they live longer. We discovered that the traditional cut point value for peak VO2, i.e. ≤ 14 mL/kg/min is not a "gender-neutral" reference since lumping HF men and women together with the same VO2 value is unlikely to describe the true risk. These preliminary findings do underline the need to assimilate gender-specific issues into clinical practice in HF, when appropriate.
BACKGROUND: Peak oxygen consumption (VO2) predictive authority in heart failure (HF) has been established from male cohorts. We evaluated the gender impact on the prognostic meaning of low peak VO2. METHODS: We followed 529 HF patients (116 female), with peak VO2 ≤ 14 mL/kg/min, until cardiovascular death (CVD) and urgent heart transplantation. RESULTS: During follow up, 156 (29%) patients had cardiac events. Female gender, age, left ventricular ejection fraction, peak VO2, peak systolic blood pressure, and beta-blocker treatment all contributed to increase the risk ability of the hierarchical multivariate model. Two-year survival was higher in women: 85 vs 66%; χ(2)=15.7, p<0.0001. Peculiarly, outcome results were similar when only CVD was considered. Females showed a multivariate adjusted hazard ratio (HR) of 0.46. Since a 1-mL/kg/min increment in peak VO2 was equated with a 12% improvement in prognosis, the same gender adjusted HR was achieved when mean peak VO2 was reduced by 5 units in women: thus, a HF woman with peak VO2 of 9 mL/kg/min has the same 2-year outcome as a HF man with peak VO2 of 14 mL/kg/min. CONCLUSIONS: Although HF women have a comparatively lower peak VO2 than men, they live longer. We discovered that the traditional cut point value for peak VO2, i.e. ≤ 14 mL/kg/min is not a "gender-neutral" reference since lumping HF men and women together with the same VO2 value is unlikely to describe the true risk. These preliminary findings do underline the need to assimilate gender-specific issues into clinical practice in HF, when appropriate.
Authors: Gerson Cipriano; Vivian T F Cipriano; Vinicius Z Maldaner da Silva; Graziella F B Cipriano; Gaspar R Chiappa; Alexandra C G B de Lima; Lawrence P Cahalin; Ross Arena Journal: Heart Fail Rev Date: 2014-09 Impact factor: 4.214
Authors: Brittany Butts; Javed Butler; Sandra B Dunbar; Elizabeth J Corwin; Rebecca A Gary Journal: Med Sci Sports Exerc Date: 2017-06 Impact factor: 5.411
Authors: Steven J Keteyian; Mahesh Patel; William E Kraus; Clinton A Brawner; Timothy R McConnell; Ileana L Piña; Eric S Leifer; Jerome L Fleg; Gordon Blackburn; Gregg C Fonarow; Paul J Chase; Lucy Piner; Marianne Vest; Christopher M O'Connor; Jonathan K Ehrman; Mary N Walsh; Gregory Ewald; Dan Bensimhon; Stuart D Russell Journal: J Am Coll Cardiol Date: 2016-02-23 Impact factor: 24.094
Authors: William Eysenck; Jet van Zalen; Nick Freemantle; Guy Lloyd; Stephen Furniss; Neil Sulke Journal: J Clin Hypertens (Greenwich) Date: 2019-07-26 Impact factor: 3.738
Authors: Jack O Garnham; Lee D Roberts; Talia Caspi; Moza M Al-Owais; Max Bullock; Peter P Swoboda; Aaron Koshy; John Gierula; Maria F Paton; Richard M Cubbon; Mark T Kearney; T Scott Bowen; Klaus K Witte Journal: J Cachexia Sarcopenia Muscle Date: 2019-08-20 Impact factor: 12.910
Authors: Serlie Fatrin; Nduka C Okwose; Kristian Bailey; Lazar Velicki; Dejana Popovic; Arsen Ristic; Petar M Seferovic; Guy A MacGowan; Djordje G Jakovljevic Journal: BMC Cardiovasc Disord Date: 2022-09-16 Impact factor: 2.174
Authors: G Thomas; M A West; M P W Grocott; D Z H Levett; M Browning; G Minto; M Swart; K Richardson; L McGarrity; S Jack Journal: Perioper Med (Lond) Date: 2020-06-04